| Name | Title | Contact Details |
|---|
Coffey Communications, Inc., is the leading provider of custom communication products for the health care industry. For more than 19 years, we have been providing clients with a full line of communication tools including: Publications for hospitals and
Medical Transportation Solutions is a State College, PA-based company in the Healthcare, Pharmaceuticals, & Biotech sector.
Based in the heart of Silicon Valley, Lumiata is an Artificial Intelligence company purpose-built for the healthcare industry. Powered by over 100 million patient data records, clinical, risk, and financial algorithms, Lumiata employs some of the nation`s leading data science and machine learning talent. Lumiata enriches payers` and providers` analytic and predictive capabilities with a platform and pre-built models that help to manage healthcare costs and risk.
A global decentralized health platform that empowers patients with a self-sovereign health identity and aligns patients, providers, and payers to battle the global pandemic of chronic disease
Neuralstem is a dual platform regenerative medicine company. The company`s technology enables the production of regionally specific, physiologically relevant neural stem cells for therapeutic use for the treatment of central nervous system (CNS) diseases and has enabled the discovery of a library of patented small molecule neurogenic compounds to treat psychological and cognitive disorders. Neuralstem`s small molecule drug discovery program screens human neural stem cell lines for compounds that may stimulate neurogenesis in the brain, possibly reversing pathologies associated with certain CNS conditions. The company`s lead compound, NSI-189, has completed FDA Phase Ia and Ib safety trials for the treatment of major depressive disorder (MDD). Neuralstem is expecting to launch a Phase II study for MDD in 2015. Neuralstem`s first stem cell therapy product, NSI-566, a spinal cord-derived neural stem cell line, is in ongoing clinical trials to treat amyotrophic lateral sclerosis (ALS, or Lou Gehrig`s disease), for which it has received orphan status designation by the FDA. Dosing in a phase IIa trial was completed in July, 2014. The next trial is anticipated to commence in 2015. In addition to ALS, the company is conducting an NSI-566 Phase I trial in chronic spinal cord injury, with NSI-566 clinical development also underway to treat ischemic